Springfield, Missouri
Owned site, currently being retrofitted for hybrid peptide synthesis.
Why NPS
Quieter than the competition.
More precise.
Ro, Hims and Hers are distribution layers. We own the pharmacy — and we can show you what is in the vial.
whynps.heroPage hero
Molecule → pharmacy → patient
Most telehealth brands buy their medicine.
We make ours.
Ro, Hims and Hers are distribution layers. NPS owns the pharmacy that compounds your prescription — and is building the American supply behind it.
- 01 From 2028
Own the molecule
Two Missouri API plants, coming online in 2028 and 2029, built for hybrid peptide synthesis.
- 02 Today
Own the pharmacy
Licensed 503A pharmacies we own outright, compounding every order to prescription.
- 03 Today
Own the patient
No middleman between the pharmacy and your door.
We are honest about the clock: today we own and operate the pharmacies and test every batch. Our own synthesis comes online in 2028.
The problem
Most peptides sold in America
are not what the label says.
This is category education, not an attack on any company. The numbers come from independent testing.
- 5–75% of label claim
Independent testing of gray-market peptides found purity 5–75% below label claim.
- ~55% of demand
Roughly 55% of demand sits in illegal channels.
The same testing found heavy-metal contamination above injectable limits, endotoxin above USP <85>, mislabeled sequences, residual solvent above ICH limits, and absent sterility testing.
Sources: University of Western States counterfeit peptide study, 2024; NABP, 2025; USP <71>, <85> and <788>.
The Quality Charter
Four rules we don’t bend.
Capacity, channel and geography are replicable. Quality discipline is not.
- I
Tier-1 API only
Tier-1 API only — sourced from U.S. and allied producers, with auditable COA, chiral panel and residual-solvent data on every lot.
- II
Per-batch release
Per-batch release: LC-MS/MS identity, HPLC potency, LAL endotoxin, USP <71> sterility, USP <788> particulates. QP sign-off mandatory.
- III
cGMP discipline
cGMP discipline under 21 CFR §211 from day one — process validation, environmental monitoring, change control, deviation tracking.
- IV
BIOSECURE-resilient
BIOSECURE-resilient two-vendor sourcing, with vial-level serialization.
What we're building
Two Missouri plants.
2028 and 2029.
This is the part of the story that is not true yet, and we would rather you heard that from us.
St. Joseph, Missouri
A build-to-suit facility that joins the network a year later.
How the molecule will be made
- 01Raw materialsFmoc amino acids, resin, reagents
- 02Hybrid synthesisSolid and solution phase
- 03CleaveTFA cleavage and deprotection
- 04PurifyPreparative HPLC
- 05LyophilizeBulk drying and QC release
- 06Bulk APIcGMP, ICH Q7
This chain describes the plants that come online in 2028 and 2029. It is not how the vial you would receive today is prepared. Today the API is sourced from Tier-1 U.S. and allied producers and tested on arrival; compounding happens in the 503A pharmacies we own.
The plant that already exists
Nortian Group, our operating sponsor, already runs a 160,000 sq ft peptide facility in Springfield, Missouri.
That facility produces hydrolyzed bovine collagen peptides — a different product from the synthetic clinical peptides dispensed here. We mention it as evidence that the group knows how to build and run a plant, not as the source of any preparation on this site.
Regulatory context
What the July 2026 PCAC vote did, and did not, do.
In April 2026 the FDA published a Federal Register notice on peptide compounding. On 23–24 July 2026 the Pharmacy Compounding Advisory Committee voted to recommend several peptides for Category 1 compoundability. A second docket is expected in February 2027.
An advisory-committee recommendation is not FDA approval, and it is not an endorsement of safety or efficacy.
- Covered: BPC-157, TB-500, KPV, MOTS-c
- Not part of that recommendation: Epitalon, Semax
We publish both lists because “our peptides are FDA-recommended” would be false for a third of our catalog.
Made in America
What we can honestly say today.
Compounding happens in the United States, in pharmacies we own. That is true now, and it is what our footer says.
Until our Missouri plants come online in 2028, the active ingredient comes from a two-vendor Tier-1 supply chain that is Western-aligned and BIOSECURE-resilient — but not necessarily U.S.-origin. The FTC’s “Made in USA” standard requires that all or virtually all of a product be American-made, so we do not make that unqualified claim yet.
When the plants are running, the claim changes and we will say so then.